BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Myeloid Leukemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Myeloid Leuke
 mia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03147612-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03147612)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Pat
 ients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute 
 Lymphoblastic Leukemia\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06817720-2925@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270307
DTEND;VALUE=DATE:20270308
SUMMARY:Olverembatinib: Phase 2 readout est. (NCT06817720)
DESCRIPTION:Olverembatinib\, phase 2\, Chronic Myeloid Leukemia.\nStudy: Ph
 ase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monothe
 rapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Fail
 ing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor o
 r Asciminib\nEstimated primary completion: 7 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/olverembatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06817720
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423911-2925@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06423911)
DESCRIPTION:Olverembatinib\, phase 3\, Chronic Myeloid Leukemia.\nStudy: St
 udy of Olverembatinib (HQP1351) in Patients With CML-CP\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06423911
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT01424982)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patien
 ts With Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0142
 4982
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03263572)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Pa
 tients With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Re
 lapsed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514534-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20290217
DTEND;VALUE=DATE:20290218
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT06514534)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I 
 Mutation Who Are Resistant\, Intolerant or Ineligible to Ponatinib.\nEstim
 ated primary completion: 17 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ponatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06514534
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04070443-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT04070443)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With 
 Chronic Myelogenous Leukemia in Chronic Phase\nEstimated primary completio
 n: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04070443
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01746836-10794@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT01746836)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients Wit
 h Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Ima
 tinib Mesylate\, Dasatinib\, or Nilotinib\nEstimated primary completion: 3
 1 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pona
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT01746836
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
